Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) has agreed to purchase intellectual property assets of a medication that treats side effects caused by liver failure, in the latest pharmaceutical deal.

Terms of the deal were not disclosed.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.